Market Overview

Jefferies Raises Tesla Price Target To $400: 'A Better Foundation'

Share:
Jefferies Raises Tesla Price Target To $400: 'A Better Foundation'

Tesla Inc (NASDAQ: TSLA) shares rose Monday after Jefferies boosted its target price on the stock along with a boost in its EBIT and per share earnings estimates in anticipation of revenue and earnings growth next year.

The Analyst

Phillippe Houchois maintained a Buy rating on Tesla and raised the price target from $300 to $400. 

The Thesis

It might not be completely smooth sailing in the short-term for the electric car maker, but third-quarter gross margin levels are "consistent with sustained profitability," and Tesla's average selling prices should stabilize, Houchois said in a Monday note. (See his track record here.) 

Jefferies is raising his 2020 EBIT estimate by 24% to $1.16 billion and boosting the EPS estimate for 2020 from $1.81 to $3.04.

"Stabilization in 2019 sets a better foundation for a return to growth in 2020 revenue and earnings," Houchois said. "We value the absence of legacy issues, net growth in revenue and earnings and persistent technology edge from battery to autonomous."

Price Action

Tesla shares were up 3.34% at $348.39.

Related Links:

Bulls And Bears Of The Week: Roku, Tesla, Twitter, Uber And More 

Musk Vs. Einhorn: Tesla CEO Offers Hedge Fund Manager A Pair Of Short Shorts 

Photo courtesy of Tesla. 

Latest Ratings for TSLA

DateFirmActionFromTo
Dec 2019MaintainsEqual-Weight
Dec 2019MaintainsSell
Dec 2019MaintainsOverweight

View More Analyst Ratings for TSLA
View the Latest Analyst Ratings

Posted-In: electric vehicles EVs Jefferies Philippe HouchoisAnalyst Color Price Target Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (TSLA)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
ABBBarclaysInitiates Coverage On
DPLOWilliam BlairUpgrades
SUPVItau BBADowngrades
GGALItau BBADowngrades
BMAItau BBADowngrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Medicine Man Technologies Reports Q3 Net Loss Of $1.83M

38 Stocks Moving In Monday's Mid-Day Session